

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 February 2025 (06.02.2025)



(10) International Publication Number
WO 2025/029842 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2024/040259

(22) International Filing Date:
31 July 2024 (31.07.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/530,142 01 August 2023 (01.08.2023) US
23196351.3 08 September 2023 (08.09.2023) EP

(71) Applicant: **PRINCIPIA BIOPHARMA INC.** [US/US];
55 Corporate Drive, Bridgewater, New Jersey 08807 (US).

(72) Inventors: **COMTE, Myriam**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **CRUCIANI, Paul**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **LARQUETOUX, Laurent**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **LATREMOLIERE, Olivier**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **LEMAITRE, Clement**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **OCHSENBEIN, Philippe**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **VERSPROUMY, Pierre**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR).

(74) Agent: **HERZFELD, Deborah** et al.; McNeill PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: PROCESS OF MAKING 2-[(3R)-2-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-L-CARBONYL]-4-METHYL-4[4-(OXETAN-3-YL)PIPERAZIN-L-YL]-PENT-2-ENENITRILE AND SOLVATE FORMS THEREOF

(57) Abstract: Disclosed herein are novel methods for preparing 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enenitrile, including various solvate forms and intermediates thereof. Also disclosed herein are novel solvate forms and intermediates of 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enenitrile.



WO 2025/029842 A2